ATE266028T1 - 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation - Google Patents

1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation

Info

Publication number
ATE266028T1
ATE266028T1 AT01930292T AT01930292T ATE266028T1 AT E266028 T1 ATE266028 T1 AT E266028T1 AT 01930292 T AT01930292 T AT 01930292T AT 01930292 T AT01930292 T AT 01930292T AT E266028 T1 ATE266028 T1 AT E266028T1
Authority
AT
Austria
Prior art keywords
dioxoisothiazolidine
inhibitors
cell proliferation
pharmaceutically acceptable
substituted indazoles
Prior art date
Application number
AT01930292T
Other languages
English (en)
Inventor
Jin Ho Lee
Chang Y Hong
Tae Sik Park
Jong Hyun Kim
Sei Hyun Choi
Sook K Yoon
Hyun Ho Chung
Shin Wu Jeong
Kwang Y Hwang
Dong Kyu Shin
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of ATE266028T1 publication Critical patent/ATE266028T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01930292T 2000-05-10 2001-05-10 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation ATE266028T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000024861 2000-05-10
PCT/KR2001/000759 WO2001085726A1 (en) 2000-05-10 2001-05-10 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation

Publications (1)

Publication Number Publication Date
ATE266028T1 true ATE266028T1 (de) 2004-05-15

Family

ID=19668316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930292T ATE266028T1 (de) 2000-05-10 2001-05-10 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation

Country Status (10)

Country Link
US (1) US6620831B2 (de)
EP (1) EP1280802B1 (de)
JP (1) JP2003532730A (de)
KR (1) KR100423899B1 (de)
CN (1) CN1432015A (de)
AT (1) ATE266028T1 (de)
AU (1) AU2001256834A1 (de)
CA (1) CA2408448A1 (de)
DE (1) DE60103147T2 (de)
WO (1) WO2001085726A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147214B1 (de) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York Neues verfahren zum erschaffen von proteinkinase-inhibitoren
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
KR100406634B1 (ko) * 2001-03-12 2003-11-20 주식회사 엘지생명과학 3,5-디아미노인다졸 유도체, 그의 제조방법 및 사이클린의존성 키나아제 저해제로서의 그의 용도
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
AU2002353186A1 (en) * 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
BRPI0507278A (pt) * 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
FR2867778B1 (fr) 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
US7691888B2 (en) * 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7632854B2 (en) * 2004-11-17 2009-12-15 Pfizer Italia S.R.L. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN107441097A (zh) 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore
KR101661723B1 (ko) * 2015-06-09 2016-10-05 계명대학교 산학협력단 2-([1,1''-바이페닐]-4-일)-ｎ-(5-(1,1-다이옥사이도아이소티아졸리딘-2-일)-1ｈ-인다졸-3-일)아세트아마이드를 유효성분으로 포함하는 자궁근종 예방 또는 치료용 조성물
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
CN113912597B (zh) * 2020-07-07 2023-06-13 赛诺哈勃药业（成都）有限公司 一类RORγ抑制剂、其制备方法及其在医药上的应用
EP4499612A1 (de) * 2022-03-30 2025-02-05 Nerviano Medical Sciences S.r.l. Substituierte 3-aminoindazolderivate als kinasehemmer
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
WO2025175264A1 (en) * 2024-02-17 2025-08-21 Padarn Therapeutics, Inc. Inhibitors of cdk2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (de) 1986-04-11 1989-02-04 Hoechst India
GB2216875B (en) 1988-04-06 1992-01-08 Motorola Ltd Container
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
ES2301194T3 (es) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
ATE309991T1 (de) * 1997-04-28 2005-12-15 Us Health Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs
ES2172882T3 (es) * 1997-05-08 2002-10-01 Pfizer Prod Inc Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
EP1017394B1 (de) * 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin-abhängige-kinase inhibierende purinderivate
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
EP1043998B1 (de) * 1997-12-13 2007-03-07 Bristol-Myers Squibb Company VERWENDUNG VON PYRAZOLO [ 3,4-b] PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

Also Published As

Publication number Publication date
US6620831B2 (en) 2003-09-16
JP2003532730A (ja) 2003-11-05
EP1280802A4 (de) 2003-06-11
CA2408448A1 (en) 2001-11-15
DE60103147D1 (de) 2004-06-09
WO2001085726A1 (en) 2001-11-15
US20030149034A1 (en) 2003-08-07
EP1280802B1 (de) 2004-05-06
DE60103147T2 (de) 2005-05-04
EP1280802A1 (de) 2003-02-05
KR100423899B1 (ko) 2004-03-24
KR20010103618A (ko) 2001-11-23
CN1432015A (zh) 2003-07-23
AU2001256834A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
DE60103147D1 (de) 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR027548A1 (es) Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
EA200000488A1 (ru) Замена катехина на биоизостеру индазола в терапевтически активных соединениях
BG106585A (en) Kinase inhibitors as therapeutic agents
PH12012501386A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
EP1631548A4 (de) Hemmer der akt aktivität
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
YU35601A (sh) SUPSTITUISANI PIRAZOLI KAO INHIBITORI p38 KINAZE
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MXPA05000388A (es) Derivados de flavona como inhibidores de cinasas dependientes de la ciclina.
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
GB0308201D0 (en) Novel compounds
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
AU4888401A (en) Sulfonamide derivative as a matrix metalloproteinase inhibitor
PT941221E (pt) Dihidrobenzofuranos substituidos como inibidores de fosfodiesterase (pde)
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties